JP2019507354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507354A5 JP2019507354A5 JP2018559674A JP2018559674A JP2019507354A5 JP 2019507354 A5 JP2019507354 A5 JP 2019507354A5 JP 2018559674 A JP2018559674 A JP 2018559674A JP 2018559674 A JP2018559674 A JP 2018559674A JP 2019507354 A5 JP2019507354 A5 JP 2019507354A5
- Authority
- JP
- Japan
- Prior art keywords
- history
- less
- biomarkers
- determining
- intervention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 57
- 208000010125 myocardial infarction Diseases 0.000 claims description 45
- 238000004393 prognosis Methods 0.000 claims description 34
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 31
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 claims description 31
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 claims description 25
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims description 25
- 102000016776 Midkine Human genes 0.000 claims description 22
- 108010092801 Midkine Proteins 0.000 claims description 22
- 208000029078 coronary artery disease Diseases 0.000 claims description 20
- 102000004264 Osteopontin Human genes 0.000 claims description 19
- 108010081689 Osteopontin Proteins 0.000 claims description 19
- 108010076365 Adiponectin Proteins 0.000 claims description 18
- 102000011690 Adiponectin Human genes 0.000 claims description 18
- 210000004556 brain Anatomy 0.000 claims description 17
- 230000000747 cardiac effect Effects 0.000 claims description 17
- 239000002934 diuretic Substances 0.000 claims description 17
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 17
- 230000001452 natriuretic effect Effects 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 210000004351 coronary vessel Anatomy 0.000 claims description 16
- 238000003745 diagnosis Methods 0.000 claims description 14
- 230000000414 obstructive effect Effects 0.000 claims description 12
- 108010087614 Apolipoprotein A-II Proteins 0.000 claims description 10
- 102000009081 Apolipoprotein A-II Human genes 0.000 claims description 10
- 238000001631 haemodialysis Methods 0.000 claims description 10
- 230000000322 hemodialysis Effects 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 9
- 101710188053 Protein D Proteins 0.000 claims description 9
- 101710132893 Resolvase Proteins 0.000 claims description 9
- 239000003580 lung surfactant Substances 0.000 claims description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
- 102000007592 Apolipoproteins Human genes 0.000 claims description 8
- 108010071619 Apolipoproteins Proteins 0.000 claims description 8
- 238000002399 angioplasty Methods 0.000 claims description 8
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 8
- 102000004237 Decorin Human genes 0.000 claims description 7
- 108090000738 Decorin Proteins 0.000 claims description 7
- 102000004890 Interleukin-8 Human genes 0.000 claims description 7
- 108090001007 Interleukin-8 Proteins 0.000 claims description 7
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 claims description 7
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 7
- 102000036675 Myoglobin Human genes 0.000 claims description 7
- 108010062374 Myoglobin Proteins 0.000 claims description 7
- 238000007887 coronary angioplasty Methods 0.000 claims description 7
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 7
- 229940096397 interleukin-8 Drugs 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 210000000130 stem cell Anatomy 0.000 claims description 7
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims description 5
- 102000011772 Apolipoprotein C-I Human genes 0.000 claims description 5
- 108010076807 Apolipoprotein C-I Proteins 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 229910002651 NO3 Inorganic materials 0.000 claims description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 4
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 4
- 239000003524 antilipemic agent Substances 0.000 claims description 4
- 239000002876 beta blocker Substances 0.000 claims description 4
- 229940097320 beta blocking agent Drugs 0.000 claims description 4
- 230000037213 diet Effects 0.000 claims description 4
- 235000005911 diet Nutrition 0.000 claims description 4
- 229940066294 lung surfactant Drugs 0.000 claims description 4
- 230000005586 smoking cessation Effects 0.000 claims description 4
- 230000000391 smoking effect Effects 0.000 claims description 4
- -1 stem cell factor Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
- 229940127218 antiplatelet drug Drugs 0.000 claims description 2
- 238000010968 computed tomography angiography Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 238000009662 stress testing Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 description 18
- 239000000523 sample Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 210000005167 vascular cell Anatomy 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021097387A JP7403498B2 (ja) | 2016-02-01 | 2021-06-10 | 心臓血管疾患及び事象のための診断及び予後方法 |
| JP2022150335A JP2022171936A (ja) | 2016-02-01 | 2022-09-21 | 心臓血管疾患及び事象のための診断及び予後方法 |
| JP2024214563A JP2025029196A (ja) | 2016-02-01 | 2024-12-09 | 心臓血管疾患及び事象のための診断及び予後方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662289513P | 2016-02-01 | 2016-02-01 | |
| US62/289,513 | 2016-02-01 | ||
| US201662378535P | 2016-08-23 | 2016-08-23 | |
| US62/378,535 | 2016-08-23 | ||
| PCT/US2017/016081 WO2017136464A1 (en) | 2016-02-01 | 2017-02-01 | Diagnostic and prognostic methods for cardiovascular diseases and events |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021097387A Division JP7403498B2 (ja) | 2016-02-01 | 2021-06-10 | 心臓血管疾患及び事象のための診断及び予後方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507354A JP2019507354A (ja) | 2019-03-14 |
| JP2019507354A5 true JP2019507354A5 (enExample) | 2020-03-12 |
| JP7134870B2 JP7134870B2 (ja) | 2022-09-12 |
Family
ID=59500904
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559674A Active JP7134870B2 (ja) | 2016-02-01 | 2017-02-01 | 心臓血管疾患及び事象のための診断及び予後方法 |
| JP2021097387A Active JP7403498B2 (ja) | 2016-02-01 | 2021-06-10 | 心臓血管疾患及び事象のための診断及び予後方法 |
| JP2022150335A Pending JP2022171936A (ja) | 2016-02-01 | 2022-09-21 | 心臓血管疾患及び事象のための診断及び予後方法 |
| JP2024214563A Pending JP2025029196A (ja) | 2016-02-01 | 2024-12-09 | 心臓血管疾患及び事象のための診断及び予後方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021097387A Active JP7403498B2 (ja) | 2016-02-01 | 2021-06-10 | 心臓血管疾患及び事象のための診断及び予後方法 |
| JP2022150335A Pending JP2022171936A (ja) | 2016-02-01 | 2022-09-21 | 心臓血管疾患及び事象のための診断及び予後方法 |
| JP2024214563A Pending JP2025029196A (ja) | 2016-02-01 | 2024-12-09 | 心臓血管疾患及び事象のための診断及び予後方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10983135B2 (enExample) |
| EP (2) | EP4574024A3 (enExample) |
| JP (4) | JP7134870B2 (enExample) |
| KR (1) | KR20180101595A (enExample) |
| CN (2) | CN108700596A (enExample) |
| AU (1) | AU2017214469A1 (enExample) |
| BR (1) | BR112018015698A2 (enExample) |
| CA (1) | CA3012192A1 (enExample) |
| MA (1) | MA43980A (enExample) |
| MX (1) | MX2018009304A (enExample) |
| RU (1) | RU2018130866A (enExample) |
| SG (1) | SG11201805906WA (enExample) |
| WO (1) | WO2017136464A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108700596A (zh) | 2016-02-01 | 2018-10-23 | 普雷西奥公司 | 用于心血管疾病和事件的诊断和预后方法 |
| EP3682240B1 (en) * | 2017-09-14 | 2024-01-24 | Laboratory Corporation of America Holdings | Assessing myocardial infarction and serious infection risk in rheumatoid arthritis patients |
| CA3081752A1 (en) * | 2017-11-02 | 2019-05-09 | Prevencio, Inc. | Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes |
| US11009452B2 (en) * | 2018-01-26 | 2021-05-18 | Viavi Solutions Inc. | Reduced false positive identification for spectroscopic quantification |
| ES3017793T3 (en) * | 2019-02-20 | 2025-05-13 | Fundacio Inst Dinvestigacio En Ciencies De La Salut Germans Trias I Pujol | In vitro method for predicting mortality risk in patients suffering from cardiogenic shock |
| CN110232975A (zh) * | 2019-05-20 | 2019-09-13 | 郑州大学第一附属医院 | 一种对糖尿病肾病患者3年内进入到肾脏替代治疗风险预测的方法 |
| CN110491512A (zh) * | 2019-08-08 | 2019-11-22 | 郑州大学第一附属医院 | 一种对肾活检确诊糖尿病肾病患者3年内进入到终末期肾脏病风险预测的方法 |
| CN110596399B (zh) * | 2019-08-29 | 2022-07-22 | 首都医科大学附属北京安贞医院 | 检测血管生成素样蛋白8含量的物质的应用 |
| CN110970131B (zh) * | 2019-10-24 | 2024-01-26 | 中国医科大学附属盛京医院 | 一种基于免疫球蛋白定量检测的肾小球疾病分类分型模型及其应用 |
| RU2726314C1 (ru) * | 2019-11-15 | 2020-07-14 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ раннего прогнозирования риска острого повреждения почек у пациентов с ишемической болезнью сердца после реваскуляризации миокарда методом аортокоронарного шунтирования |
| RU2760445C1 (ru) * | 2020-11-13 | 2021-11-25 | Виталий Юрьевич Мишланов | Способ диагностики патологических состояний человека |
| WO2022202360A1 (ja) * | 2021-03-23 | 2022-09-29 | テルモ株式会社 | 情報処理装置、情報処理方法およびプログラム |
| CN113342963B (zh) * | 2021-04-29 | 2022-03-04 | 山东大学 | 一种基于迁移学习的服务推荐方法及系统 |
| RU2770550C1 (ru) * | 2021-05-31 | 2022-04-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования сердечно-сосудистого риска с помощью определения уровня эстрогенов |
| EP4500552A2 (en) * | 2022-03-30 | 2025-02-05 | Inflammatix, Inc. | Methods for diagnosing myocardial infarction |
| CN114974576A (zh) * | 2022-07-12 | 2022-08-30 | 曜立科技(北京)有限公司 | 一种基于元数据的心脑血管数疾病诊断管理系统 |
| CN115185936B (zh) | 2022-07-12 | 2023-02-03 | 曜立科技(北京)有限公司 | 一种基于大数据的医疗临床数据质量分析系统 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US20080202927A1 (en) | 2000-11-03 | 2008-08-28 | Clinical Micro Sensors, Inc. | Devices and methods for biochip multiplexing |
| US20030134433A1 (en) | 2002-01-16 | 2003-07-17 | Nanomix, Inc. | Electronic sensing of chemical and biological agents using functionalized nanostructures |
| US20060228723A1 (en) | 2002-01-16 | 2006-10-12 | Keith Bradley | System and method for electronic sensing of biomolecules |
| US9234867B2 (en) | 2003-05-16 | 2016-01-12 | Nanomix, Inc. | Electrochemical nanosensors for biomolecule detection |
| US8685711B2 (en) | 2004-09-28 | 2014-04-01 | Singulex, Inc. | Methods and compositions for highly sensitive detection of molecules |
| US20080269346A1 (en) * | 2005-02-17 | 2008-10-30 | University Of Florida Research Foundation, Inc. | B-Blocker Pharmacogenetics in Heart Failure |
| CN101495862A (zh) * | 2005-06-24 | 2009-07-29 | 利兰·斯坦福青年大学托管委员会 | 诊断和监测动脉粥样硬化性心血管疾病的方法和组合物 |
| US8093017B2 (en) * | 2005-12-07 | 2012-01-10 | Siemens Heathcare Diagnostics Inc. | Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics |
| US20100331200A1 (en) * | 2006-03-31 | 2010-12-30 | Gordon Neal F | Post translational modification pattern analysis |
| EP2924440A3 (en) * | 2006-06-07 | 2016-03-09 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| WO2008045799A2 (en) | 2006-10-06 | 2008-04-17 | Nanomix, Inc. | Electrochemical nanosensors for biomolecule detection |
| PL2084543T3 (pl) * | 2006-10-26 | 2018-04-30 | B.R.A.H.M.S Gmbh | Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II |
| EP2147115A4 (en) * | 2007-04-16 | 2010-05-05 | CARDIOBIOINDEX / CARDIOBIOSCORE AND THE USE OF THE SPOKING PROTEOME IN CARDIOVASCULAR DIAGNOSTICS | |
| US20100119600A1 (en) | 2007-06-01 | 2010-05-13 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
| GB0717637D0 (en) | 2007-09-10 | 2007-10-17 | Univ Leiden | Future cardiac event biomarkers |
| US20100267062A1 (en) * | 2007-09-26 | 2010-10-21 | Norbert Frey | Osteopontin as Novel Prognostic Biomarker for Heart Failure |
| US8241861B1 (en) | 2008-07-08 | 2012-08-14 | Insilicos, Llc | Methods and compositions for diagnosis or prognosis of cardiovascular disease |
| RU2568354C2 (ru) | 2009-06-04 | 2015-11-20 | Конинклейке Филипс Электроникс, Н.В. | Способ и система обеспечения поведенческой терапии для лечения бессонницы |
| JP5678045B2 (ja) * | 2009-06-08 | 2015-02-25 | シンギュレックス・インコーポレイテッド | 高感度バイオマーカーパネル |
| WO2011022628A1 (en) * | 2009-08-20 | 2011-02-24 | The Board Of Regents Of The University Of Texas System | Methods and compositions for diagnosis of acute myocardial infarction (ami) |
| US20110144914A1 (en) * | 2009-12-09 | 2011-06-16 | Doug Harrington | Biomarker assay for diagnosis and classification of cardiovascular disease |
| KR101256928B1 (ko) * | 2010-01-20 | 2013-04-19 | 주식회사디엔에이링크 | 비만 또는 당뇨에 관련된 단일염기다형성 및 그의 용도 |
| WO2012072595A1 (en) * | 2010-11-30 | 2012-06-07 | Universiteit Gent | Platelet factor 4 variant for the prognosis of cardiovascular outcome in patients having heart disease |
| BR112013022952B1 (pt) | 2011-03-09 | 2020-09-08 | Abionic Sa | Biossensor, matriz compreendendo diversos biossensores, montagem consistindo em um ou diversos biossensores e método para detectar e quantificar a presença de biomoléculas |
| US20140193846A1 (en) * | 2011-04-19 | 2014-07-10 | Scott & White Healthcare | Novel apoc-i isoforms and their use as biomarkers and risk factors of atherosclerotic disease |
| US20140011811A1 (en) * | 2011-10-06 | 2014-01-09 | The United States Government As Represented By The Department Of Veterans Affairs | Myosin binding protein-c for use in methods relating to diastolic heart failure |
| EP2920722B1 (en) * | 2012-11-16 | 2021-01-20 | Siemens Healthcare Diagnostics Inc. | Method to identify optimum coronary artery disease treatment |
| CA2953789A1 (en) | 2013-07-12 | 2015-01-15 | Emory University | Diagnostic assay to predict cardiovascular risk |
| EP3021968B1 (en) | 2013-07-17 | 2018-09-26 | Abionic SA | Method and device for bioassays |
| WO2015085314A2 (en) * | 2013-12-06 | 2015-06-11 | Diadexus, Inc. | Methods for detection of heart failure |
| WO2015171989A1 (en) * | 2014-05-08 | 2015-11-12 | University Of Maryland, Baltimore | Methods for assessing differential risk for developing heart failure |
| ES2973772T3 (es) | 2014-07-03 | 2024-06-24 | Abionic Sa | Cápsula de cuantificación molecular rápida de una muestra de fluido, tal como sangre completa |
| CN108700596A (zh) | 2016-02-01 | 2018-10-23 | 普雷西奥公司 | 用于心血管疾病和事件的诊断和预后方法 |
| JP7310591B2 (ja) | 2019-12-19 | 2023-07-19 | 株式会社オートネットワーク技術研究所 | 駆動装置 |
-
2017
- 2017-02-01 CN CN201780011650.8A patent/CN108700596A/zh active Pending
- 2017-02-01 EP EP25170203.1A patent/EP4574024A3/en active Pending
- 2017-02-01 CN CN202210116587.7A patent/CN114441773A/zh active Pending
- 2017-02-01 MA MA043980A patent/MA43980A/fr unknown
- 2017-02-01 RU RU2018130866A patent/RU2018130866A/ru not_active Application Discontinuation
- 2017-02-01 JP JP2018559674A patent/JP7134870B2/ja active Active
- 2017-02-01 KR KR1020187024496A patent/KR20180101595A/ko not_active Withdrawn
- 2017-02-01 EP EP17748086.0A patent/EP3411720B1/en active Active
- 2017-02-01 BR BR112018015698A patent/BR112018015698A2/pt not_active Application Discontinuation
- 2017-02-01 SG SG11201805906WA patent/SG11201805906WA/en unknown
- 2017-02-01 MX MX2018009304A patent/MX2018009304A/es unknown
- 2017-02-01 AU AU2017214469A patent/AU2017214469A1/en not_active Abandoned
- 2017-02-01 US US16/073,754 patent/US10983135B2/en active Active
- 2017-02-01 CA CA3012192A patent/CA3012192A1/en active Pending
- 2017-02-01 WO PCT/US2017/016081 patent/WO2017136464A1/en not_active Ceased
-
2020
- 2020-10-27 US US17/081,776 patent/US11977083B2/en active Active
-
2021
- 2021-06-10 JP JP2021097387A patent/JP7403498B2/ja active Active
-
2022
- 2022-09-21 JP JP2022150335A patent/JP2022171936A/ja active Pending
-
2023
- 2023-06-21 US US18/339,066 patent/US12146888B2/en active Active
-
2024
- 2024-10-11 US US18/913,852 patent/US20250060374A1/en active Pending
- 2024-12-09 JP JP2024214563A patent/JP2025029196A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507354A5 (enExample) | ||
| Cheong et al. | Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction | |
| Sandoval et al. | Supply/demand type 2 myocardial infarction: should we be paying more attention? | |
| Rybicki et al. | 2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMMI/STR/STS appropriate utilization of cardiovascular imaging in emergency department patients with chest pain: a joint document of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Appropriate Use Criteria Task Force | |
| Patel et al. | Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice | |
| Tsang et al. | Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography | |
| Felker et al. | A standardized definition of ischemic cardiomyopathy for use in clinical research | |
| Brown et al. | Coarctation of the aorta: lifelong surveillance is mandatory following surgical repair | |
| Goonewardena et al. | Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure | |
| Lopez-Cuenca et al. | Comparison between type-2 and type-1 myocardial infarction: clinical features, treatment strategies and outcomes | |
| JP7762680B2 (ja) | 急性冠症候群のリスクを推定するための決定木ベースのシステム及び方法 | |
| RU2018130866A (ru) | Способы диагностики и прогнозирования сердечно-сосудистых заболеваний и явлений | |
| CN119199150A (zh) | 作为对象的细胞外容量状态的标志物的MR-proADM | |
| Chou et al. | Survival of older patients with advanced CKD managed without dialysis: a narrative review | |
| Kilinc et al. | Significance of serum cardiac troponin I levels in pulmonary embolism | |
| Carmelita et al. | Prevalence of renal artery stenosis in patients undergoing cardiac catheterization | |
| Niu et al. | Association of plasma B-type natriuretic peptide concentration with myocardial infarct size in patients with acute myocardial infarction | |
| Bayar et al. | Assessment of aortic elasticity in patients with celiac disease | |
| Attia et al. | Evaluation of acute pulmonary embolism by sixty-four slice multidetector CT angiography: Correlation between obstruction index, right ventricular dysfunction and clinical presentation | |
| Kwon et al. | Predictors of ischemic stroke for low-risk patients with atrial fibrillation: a matched case-control study | |
| Won et al. | Prognostic role of sarcopenia on major adverse cardiac events among patients who underwent successful percutaneous coronary intervention: a retrospective cohort study | |
| Galeano-Valle et al. | Early surgical treatment in patients with pulmonary embolism and thrombus-in-transit | |
| Coyle et al. | Diagnostic testing in acute aortic dissection | |
| Hoshino et al. | Biomarkers of inflammation and fibrosis in young adults with history of Kawasaki disease | |
| Kong et al. | CTEPH: A Kaiser Permanente Northern California Experience |